摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3S,3aR,11aS,11bR)-3-(isoquinolin-7-yl)-3a-methyl-1,3,3a,4,5,8,9,10,11a,11b-decahydrocyclopenta[c]xanthen-7(2H)-one | 1388055-29-5

中文名称
——
中文别名
——
英文名称
(3S,3aR,11aS,11bR)-3-(isoquinolin-7-yl)-3a-methyl-1,3,3a,4,5,8,9,10,11a,11b-decahydrocyclopenta[c]xanthen-7(2H)-one
英文别名
(3S,3aR,11aS,11bR)-3-isoquinolin-7-yl-3a-methyl-1,2,3,4,5,8,9,10,11a,11b-decahydroindeno[4,5-b]chromen-7-one
(3S,3aR,11aS,11bR)-3-(isoquinolin-7-yl)-3a-methyl-1,3,3a,4,5,8,9,10,11a,11b-decahydrocyclopenta[c]xanthen-7(2H)-one化学式
CAS
1388055-29-5
化学式
C26H27NO2
mdl
——
分子量
385.506
InChiKey
YSQKPPYWORFJOF-USXZWKKNSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.6
  • 重原子数:
    29
  • 可旋转键数:
    1
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.46
  • 拓扑面积:
    39.2
  • 氢给体数:
    0
  • 氢受体数:
    3

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Short-step synthesis and structure-activity relationship of cortistatin A analogs
    作者:Naoyuki Kotoku、Aoi Ito、Shunichi Shibuya、Kanako Mizuno、Aki Takeshima、Masaki Nogata、Motomasa Kobayashi
    DOI:10.1016/j.tet.2017.01.042
    日期:2017.3
    An improved method for synthesizing structurally simplified analogs of cortistatin A (1), a novel anti-angiogenic steroidal alkaloid from a marine sponge, was developed. In contrast to previous methods, step- and redox-economical synthesis was achieved using a known α-bromoketone as the starting material. The structure-activity relationship study revealed that the isoquinoline portion was strictly recognized
    开发了一种改进的方法,用于从海洋海绵中合成皮质抑素A(1)(一种新型的抗血管生成类固醇生物碱)的结构简化类似物。与以前的方法相比,使用已知的α-溴代酮作为起始原料,可以实现分步和氧化还原经济的合成。结构-活性关系研究表明,异喹啉部分被目标分子严格识别。出人意料的是,在A环结构上引入乙酰胺部分极大地增强了对内皮细胞的选择性抗增殖活性。这种新方法可以轻松地用于克级合成,并使我们能够制备各种类似物,这些类似物侧重于侧链和A环结构的参与。
  • NOVEL CORTISTATIN A ANALOG AND USE THEREOF
    申请人:Osaka University
    公开号:EP2617720A1
    公开(公告)日:2013-07-24
    A compound represented by the general formula (M): (wherein R1 represents a substituted or unsubstituted aromatic heterocyclic group, R2 represents a hydrogen atom, a substituted or unsubstituted alkyl group having 1 to 3 carbon atoms, OR3, N(R3)2, C(=O)OR3 or C(=O)N(R3)2, R3 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms, or an acyl group having 1 to 4 carbon atoms, R4 represents a hydrogen atom, an oxygen atom or OR5, and R5 represents a hydrogen atom, an alkyl group having 1 to 3 carbon atoms, or an acyl group having 1 to 3 carbon atoms); or a pharmaceutically acceptable salt thereof is a cortistatin A analog which is useful as an active ingredient of medicaments for cancer prevention or treatment in that the analog can be mass-produced by chemical synthesis due to its simple chemical structure and retains the same biological activities as those of cortistatin A.
    通式(M)代表的化合物: (其中 R1 代表取代或未取代的芳香杂环基团、 R2 代表氢原子、具有 1 至 3 个碳原子的取代或未取代的烷基、OR3、N(R3)2、C(=O)OR3 或 C(=O)N(R3)2 R3 代表氢原子、具有 1 至 4 个碳原子的烷基或具有 1 至 4 个碳原子的酰基、 R4 代表氢原子、氧原子或 OR5,以及 R5 代表氢原子、具有 1 至 3 个碳原子的烷基或具有 1 至 3 个碳原子的酰基);或 其药学上可接受的盐是可的松素 A 类似物,可作为预防或治疗癌症药物的活性成分,因为该类似物的化学结构简单,可通过化学合成大规模生产,并保留了与可的松素 A 相同的生物活性。
  • US8791263B2
    申请人:——
    公开号:US8791263B2
    公开(公告)日:2014-07-29
  • Creation of Readily Accessible and Orally Active Analogue of Cortistatin A
    作者:Naoyuki Kotoku、Yuji Sumii、Takeshi Hayashi、Satoru Tamura、Takashi Kawachi、Sho Shiomura、Masayoshi Arai、Motomasa Kobayashi
    DOI:10.1021/ml300143d
    日期:2012.8.9
    Syntheses of structurally simplified analogues of cortistatin A (1), a novel antiangiogenic steroidal alkaloid from Indonesian marine sponge, and their biological activities were investigated. The analogues were designed by considering the 3-D structure of 1. Compound 30, in which the isoquinoline moiety was appended to the planar tetracyclic core structure, showed potent antiproliferative activity against human umbilical vein endothelial cells (HUVECs) together with high selectivity and also showed in vivo antiangiogenic activity and significant antitumor effect by oral administration.
查看更多